title: Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer.
abstract: The estrogen receptor (ER) pathway plays a critical role in breast cancer development and progression. Endocrine therapy targeting estrogen action is the most important systemic therapy for ER positive breast cancer. However its efficacy is limited by intrinsic and acquired resistance. Mechanisms responsible for endocrine resistance include deregulation of the ER pathway itself, including loss of ER expression, post-translational modification of ER, deregulation of ER co-activators; increased receptor tyrosine kinase signaling leading to activation of various intracellular pathways involved in signal transduction, proliferation and cell survival, including growth factor receptor tyrosine kinases human epidermal growth factor receptor-2, epidermal growth factor receptor, PI3K/AKT/mammalian target of rapamycin (mTOR), Mitogen activated kinase (MAPK)/ERK, fibroblast growth factor receptor, insulin-like growth factor-1 receptor; alterations in cell cycle and apoptotic machinery; Epigenetic modification including dysregulation of DNA methylation, histone modification, and nucleosome remodeling; and altered expression of specific microRNAs. Functional genomics has helped us identify a catalog of genetic and epigenetic alterations that may be exploited as potential therapeutic targets and biomarkers of response. New treatment combinations targeting ER and such oncogenic signaling pathways which block the crosstalk between these pathways have been proven effective in preclinical models. Results of recent clinical studies suggest that subsets of patients benefit from the combination of inhibitor targeting certain oncogenic signaling pathway with endocrine therapy. Especially, inhibition of the mTOR signaling pathway, a key component implicated in mediating multiple signaling cascades, offers a promising approach to restore sensitivity to endocrine therapy in breast cancer. We systematically reviewed important publications cited in PubMed, recent abstracts from ASCO annual meetings and San Antonio Breast Cancer Symposium, and relevant trials registered at ClinicalTrials.gov. We present the molecular mechanisms contributing to endocrine resistance, in particular focusing on the biological rationale for the clinical development of novel targeted agents in endocrine resistant breast cancer. We summarize clinical trials utilizing novel strategies to overcome therapeutic resistance, highlighting the need to better identify the appropriate patients whose diseases are most likely to benefit from these specific strategies.
authors.affiliation: Meng Zhao, Bhuvaneswari Ramaswamy, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University's Wexner Medical Center, Columbus, OH 43210, United States.
authors.forename: Meng
authors.initials: M
authors.lastname: Zhao
authors.affiliation: Meng Zhao, Bhuvaneswari Ramaswamy, Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, The Ohio State University's Wexner Medical Center, Columbus, OH 43210, United States.
authors.forename: Bhuvaneswari
authors.initials: B
authors.lastname: Ramaswamy
keywords: Breast cancer; Endocrine resistance; Endocrine therapy; Targeted therapy; Therapeutic advances
references.citation: Nat Rev Drug Discov. 2009 Aug;8(8):627-44
references.pmid: 19644473
references.citation: Endocr Relat Cancer. 2006 Sep;13(3):863-73
references.pmid: 16954435
references.citation: Cancer Res. 2008 Feb 1;68(3):826-33
references.pmid: 18245484
references.citation: Cancer Sci. 2008 Oct;99(10):1992-2003
references.pmid: 19016759
references.citation: Proc Natl Acad Sci U S A. 2006 May 16;103(20):7795-800
references.pmid: 16682622
references.citation: Int J Cancer. 2000 Jul 20;89(4):384-8
references.pmid: 10956414
references.citation: Nat Rev Cancer. 2002 Feb;2(2):101-12
references.pmid: 12635173
references.citation: Biochem J. 2011 Jul 15;437(2):199-213
references.pmid: 21711248
references.citation: Cancer Res. 2008 Jul 15;68(14):5628-38
references.pmid: 18632615
references.citation: Endocr Rev. 2008 Apr;29(2):217-33
references.pmid: 18216219
references.citation: Br J Cancer. 2011 Jun 7;104(12):1828-35
references.pmid: 21559012
references.citation: J Clin Oncol. 2013 Jan 10;31(2):195-202
references.pmid: 23233719
references.citation: Cell Growth Differ. 1994 Dec;5(12):1263-74
references.pmid: 7696175
references.citation: Oncologist. 2010;15(2):122-9
references.pmid: 20156908
references.citation: Chin J Cancer Res. 2012 Dec;24(4):257-8
references.pmid: 23358885
references.citation: Nat Rev Cancer. 2009 Sep;9(9):631-43
references.pmid: 19701242
references.citation: Expert Opin Ther Targets. 2011 Jul;15(7):829-46
references.pmid: 21375471
references.citation: Cancer Res. 2001 Oct 1;61(19):7025-9
references.pmid: 11585728
references.citation: Clin Cancer Res. 2013 Jul 1;19(13):3693-702
references.pmid: 23658459
references.citation: Nat Rev Cancer. 2008 Dec;8(12):915-28
references.pmid: 19029956
references.citation: Cancer Lett. 2007 Oct 18;256(1):1-24
references.pmid: 17475399
references.citation: J Clin Oncol. 2012 Mar 1;30(7):709-17
references.pmid: 22042946
references.citation: Endocr Relat Cancer. 2011 Apr 28;18(3):333-45
references.pmid: 21367843
references.citation: J Clin Oncol. 2006 Jul 1;24(19):3019-25
references.pmid: 16754938
references.citation: Cancer Res. 1995 Jun 1;55(11):2279-83
references.pmid: 7538900
references.citation: J Clin Oncol. 2009 Jun 1;27(16):2630-7
references.pmid: 19380449
references.citation: Nature. 2012 Oct 4;490(7418):61-70
references.pmid: 23000897
references.citation: J Clin Oncol. 2005 Oct 20;23(30):7721-35
references.pmid: 16234531
references.citation: Nature. 2000 Aug 17;406(6797):747-52
references.pmid: 10963602
references.citation: Lancet. 2005 May 14-20;365(9472):1687-717
references.pmid: 15894097
references.citation: Science. 2002 May 31;296(5573):1655-7
references.pmid: 12040186
references.citation: Cancer Cell. 2003 Feb;3(2):97-9
references.pmid: 12620402
references.citation: J Clin Oncol. 2008 Sep 1;26(25):4078-85
references.pmid: 18757322
references.citation: J Clin Invest. 2010 Jul;120(7):2406-13
references.pmid: 20530877
references.citation: Nucleic Acids Res. 2001 Jul 15;29(14):2905-19
references.pmid: 11452016
references.citation: Clin Cancer Res. 2011 Mar 1;17(5):1147-59
references.pmid: 21220480
references.citation: Mol Cell Biol. 1996 Dec;16(12):6917-25
references.pmid: 8943347
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5529-37
references.pmid: 19786670
references.citation: BMC Cancer. 2007 Apr 03;7:59
references.pmid: 17407600
references.citation: J Clin Oncol. 2012 Aug 1;30(22):2718-24
references.pmid: 22565002
references.citation: Annu Rev Med. 2011;62:233-47
references.pmid: 20887199
references.citation: Hum Pathol. 2004 Dec;35(12):1537-42
references.pmid: 15619214
references.citation: Lancet Oncol. 2011 Nov;12(12):1101-8
references.pmid: 22018631
references.citation: Cancer Res. 2004 Feb 15;64(4):1522-33
references.pmid: 14973112
references.citation: J Clin Oncol. 2011 Nov 20;29(33):4452-61
references.pmid: 22010023
references.citation: Gene Expr. 2011;15(3):141-51
references.pmid: 22268296
references.citation: Cancer Res. 2012 Oct 1;72(19):5048-59
references.pmid: 22875023
references.citation: Breast Cancer Res Treat. 2009 Mar;114(2):263-75
references.pmid: 18409071
references.citation: Nat Rev Endocrinol. 2014 Feb;10(2):66
references.pmid: 24275740
references.citation: Cancer Res. 2010 Jul 1;70(13):5199-202
references.pmid: 20570901
references.citation: Mol Cell. 2008 Jul 25;31(2):212-21
references.pmid: 18657504
references.citation: Breast. 2003 Dec;12(6):362-7
references.pmid: 14659106
references.citation: J Clin Oncol. 2007 Sep 1;25(25):3816-22
references.pmid: 17679728
references.citation: Breast Cancer Res Treat. 2003 Sep;81(1):81-93
references.pmid: 14531500
references.citation: Science. 2002 May 31;296(5573):1642-4
references.pmid: 12040178
references.citation: Endocr Rev. 2004 Dec;25(6):869-98
references.pmid: 15583021
references.citation: J Natl Cancer Inst. 1998 Jun 3;90(11):814-23
references.pmid: 9625169
references.citation: Oncogene. 2010 Jul 15;29(28):4018-32
references.pmid: 20473330
references.citation: Clin Cancer Res. 2010 Mar 1;16(5):1486-97
references.pmid: 20179226
references.citation: Clin Cancer Res. 2004 Sep 1;10(17):5670-6
references.pmid: 15355892
references.citation: Ann Oncol. 2007 Aug;18(8):1323-8
references.pmid: 17693645
references.citation: Ann Oncol. 2014 Mar;25(3):552-563
references.pmid: 24265351
references.citation: Lancet Oncol. 2005 Jun;6(6):383-91
references.pmid: 15925816
references.citation: Crit Rev Oncol Hematol. 2012 Nov;84(2):243-51
references.pmid: 22494933
references.citation: Nature. 2008 Dec 4;456(7222):663-6
references.pmid: 19005469
references.citation: Endocrinology. 2003 Mar;144(3):1032-44
references.pmid: 12586780
references.citation: J Clin Oncol. 2010 Aug 10;28(23):3784-96
references.pmid: 20625130
references.citation: Vitam Horm. 2005;71:201-37
references.pmid: 16112269
references.citation: J Clin Oncol. 1984 Oct;2(10):1102-9
references.pmid: 6491696
references.citation: J Clin Oncol. 2005 Apr 10;23(11):2469-76
references.pmid: 15753463
references.citation: Apoptosis. 2001 Dec;6(6):469-77
references.pmid: 11595837
references.citation: Breast Cancer Res. 2011;13(6):221
references.pmid: 22217398
references.citation: Ann Oncol. 2004 Oct;15(10):1510-6
references.pmid: 15367412
references.citation: J Clin Oncol. 2013 Jun 10;31(17):2128-35
references.pmid: 23650416
references.citation: Gynecol Oncol. 2006 Aug;102(2):292-9
references.pmid: 16443261
references.citation: Nat Rev Cancer. 2010 Feb;10(2):116-29
references.pmid: 20094046
references.citation: Breast Cancer Res Treat. 2006 Mar;96(2):131-46
references.pmid: 16261397
references.citation: Cancer Res. 2010 Mar 1;70(5):2085-94
references.pmid: 20179196
references.citation: Nat Rev Cancer. 2009 Aug;9(8):576-86
references.pmid: 19629072
references.citation: Endocr Relat Cancer. 2004 Dec;11(4):643-58
references.pmid: 15613444
references.citation: J Natl Cancer Inst. 2004 Jun 16;96(12):926-35
references.pmid: 15199112
references.citation: Curr Breast Cancer Rep. 2011 Mar;3(1):34-43
references.pmid: 23097683
references.citation: N Engl J Med. 2012 Feb 9;366(6):520-9
references.pmid: 22149876
references.citation: J Clin Oncol. 2007 Feb 10;25(5):486-92
references.pmid: 17200148
references.citation: J Biol Chem. 2011 Dec 9;286(49):42292-42302
references.pmid: 22009755
references.citation: J Clin Oncol. 2009 Nov 20;27(33):5538-46
references.pmid: 19786658
references.citation: Cancer. 2003 Nov 1;98(9):1802-10
references.pmid: 14584060
references.citation: Oncologist. 2012;17(8):1090-9
references.pmid: 22851551
references.citation: Biologics. 2012;6:289-97
references.pmid: 22956860
references.citation: Clin Cancer Res. 2010 Mar 15;16(6):1904-14
references.pmid: 20215537
references.citation: BMC Med Genomics. 2009 Jun 24;2:37
references.pmid: 19552798